Thomas D Penning - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Thomas D Penning

Showing results (31-40 of 34) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 34 results.

Journal of Medicinal Chemistry|October 1, 2024

Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with <i>In Vivo</i> Target EngagementRobin R Frey, Navendu Jana, Jacob V Gorman, et al.

Bioorganic & Medicinal Chemistry Letters|November 22, 2005

Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonistsMark L Boys, Lori A Schretzman, Nizal S Chandrakumar, et al.

Journal of Medicinal Chemistry|September 16, 2024

Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase InhibitorYiyun Yu, Miyeon Jang, Julie Miyashiro, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsCherrie K Donawho, Yan Luo, Yanping Luo, et al.

Pageof 4

Search research articles

Showing results (31-40 of 34) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 34 results.

Journal of Medicinal Chemistry|October 1, 2024

Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with <i>In Vivo</i> Target EngagementRobin R Frey, Navendu Jana, Jacob V Gorman, et al.

Bioorganic & Medicinal Chemistry Letters|November 22, 2005

Journal of Medicinal Chemistry|September 16, 2024

Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase InhibitorYiyun Yu, Miyeon Jang, Julie Miyashiro, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsCherrie K Donawho, Yan Luo, Yanping Luo, et al.

Pageof 4